Hemab Therapeutics Holdings, Inc. (COAG)

NASDAQ: COAG · USD

$38.5

+0.09 (+0.2%)· Recorded snapshot

Market cap	1.8B
Net income (ttm)	-83.2M
EPS (ttm)	-$10.1
Shares out	46.7M
Volume	341,651

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -83.2M
EPS (ttm): -$10.1
Market cap: 1.8B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All COAG indicators

Market & fundamental data

Available fields

143

Groups with data

Currency

USD

Showing 143 of 143 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002114044
Company name	Hemab Therapeutics Holdings, Inc.
Country	United States
Country code	US
CUSIP number	423494103
Earnings date	2026-11-09
Earnings time	amc
Enterprise value	$1.3B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2020
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2026-05-01
Is primary listing	Yes
Is SPAC	No
ISIN number	US4234941031
Last earnings date	2026-08-11
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.8B
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	No
Price	$38.49
Price currency	USD
Sector	Healthcare
SIC code	2836
Stock price date	2026-10-28
Symbol	COAG
U.S. state	Massachusetts
Website	https://www.hemab.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-26.12%
FCF / EV yield	-5.82%
FCF yield	-4.33%
P/B ratio	3.95x
Price / tangible book value	3.94x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
ROCE	-19.17%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	1
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-135,000
Depreciation and amortization	$300,000
EBIT	$-87.2M
EBITDA	$-86.9M
EPS	$-10.06
FCF per share	$-1.66
Financing cash flow	$473.5M
Free cash flow	$-77.5M
Free cash flow minus SBC	$-81.9M
Income taxes	$68,000
Investing cash flow	$-220.3M
Net borrowing	$-107,000
Net cash flow	$175.9M
Net income	$-83.2M
Operating cash flow minus SBC	$-81.7M
Operating income	$-87.2M
Stock-based compensation	$4.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$9.73
Debt / equity	0
Long-term assets	$3.8M
Long-term liabilities	$566,000
Net cash (debt)	$456.4M
Net cash / market cap	25.53%
Net debt / equity	-1
Piotroski F-Score	1
Property, plant and equipment	$1.5M
Shareholders' equity	$454.3M
Tangible book value	$454.3M
Tangible book value per share	$9.73
Total assets	$467.8M
Total cash	$457.5M
Total debt	$1M
Total liabilities	$13.5M

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$464M
Current liabilities	$12.9M
Current ratio	35.85
Net working capital	$-5.9M
Quick ratio	35.48
Working capital	$451.1M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Dividend yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1D price change	0.23%
1M price change	10.02%
1M total return	10.02%
1W price change	11.85%
1W total return	11.85%
20-day SMA	$32.43
3M price change	-24.15%
3M total return	-24.15%
50-day SMA	$38.26
52-week high	$55.42
52-week high date	2026-08-14
52-week low	$23.00
52-week low date	2026-05-11
All-time high	$55.42
All-time high date	2026-08-14
All-time low	$23.00
All-time low date	2026-05-11
Average true range (ATR)	$2.54
Average volume	372.8K
Beta (1Y)	-0.57
Change from 52-week high	-30.55%
Change from 52-week low	67.35%
Change from all-time high	-31.04%
Change from all-time low	66.17%
Change from open	1.29%
Day's gap	-1.04%
Dollar volume	$13.2M
High price	$38.52
Low price	$37.56
Monthly RSI	0
Open price	$38.00
Position in 52-week range	96.87%
Premarket change	0%
Premarket close	$38.40
Premarket price	$38.40
Previous close	$38.40
Price vs 20-day SMA	17.87%
Price vs 50-day SMA	-0.1%
Relative volume	0.92
Return from IPO open	41.78%
Return from IPO price	112.67%
RSI	60.12
Sharpe ratio	0.67
Sortino ratio	1.03
Volume	341.7K
Weekly RSI	49.45

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	20.3M
Float percentage	43.48%
Shares change (QoQ)	3,083.02%
Shares held by insiders	0.26%
Shares held by institutions	44.92%
Shares outstanding	46.7M
Short % of float	16.69%
Short % of shares	7.26%
Short ratio	5.7 days

Deeper analysis on COAG

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this COAG report

Is a complete COAG research report available?

No complete published report is available for Hemab Therapeutics Holdings, Inc. (COAG) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Hemab Therapeutics Holdings, Inc. (COAG)

Price

Financial snapshot

Fair-value bridge

Latest news · COAG

Valuation

Balance sheet

Trading

Next earnings

Sector percentile context

All COAG indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on COAG

Frequently asked questions